Pasar al contenido principal

INTERACCIONES DEL TUMOR Y SU MICROAMBIENTE COMO FUENTE DE NUEVOS BIOMARCADORES Y DIANAS TERAPEUTICAS PARA EL DIAGNOSTICO Y MANEJO CLINICO DE PACIENTES CON CANCER DE CABEZA Y CUELLO

PI19/00560

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION E INNOVACION BIOSANITARIA EN EL PRINCIPADO DE ASTURIAS (FINBA)
Centro realización INSTITUTO DE INVESTIGACION SANITARIA DEL PRINCIPADO DE ASTURIAS (ISPA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

TSPAN1: A Novel Protein Involved in Head and Neck Squamous Cell Carcinoma Chemoresistance

  • Mir Perez, Cristina
  • Carballo Perich, Laia
  • Castellví Vives, Josep
  • Lorente Guerrero, Juan
  • Benavente Norza, Sergio
  • Lleonart Pajarin, Matilde
  • Temprana Salvador, Jordi
  • Garcia Mayea, Yoelsis
Apoptosi; Cèl·lules mare del càncer; Resistència, Apoptosis; Células madre cancerosas; Resistencia, Apoptosis; Cancer stem cells; Resistance, Sensitization of resistant cells and cancer stem cells (CSCs) represents a major challenge in cancer therapy. A proteomic study revealed tetraspanin-1 (TSPAN1) as a protein involved in acquisition of cisplatin (CDDP) resistance (Data are available via ProteomeXchange with identifier PXD020159). TSPAN1 was found to increase in CDDP-resistant cells, CSCs and biopsies from head and neck squamous cell carcinoma (HNSCC) patients. TSPAN1 depletion in parental and CDDP-resistant HNSCC cells reduced cell proliferation, induced apoptosis, decreased autophagy, sensitized to chemotherapeutic agents and inhibited several signaling cascades, with phospho-SRC inhibition being a major common target. Moreover, TSPAN1 depletion in vivo decreased the size and proliferation of parental and CDDP-resistant tumors and reduced metastatic spreading. Notably, CDDP-resistant tumors showed epithelial–mesenchymal transition (EMT) features that disappeared upon TSPAN1 inhibition, suggesting a link of TSPAN1 with EMT and metastasis. Immunohistochemical analysis of HNSCC specimens further revealed that TSPAN1 expression was correlated with phospho-SRC (pSRC), and inversely with E-cadherin, thus reinforcing TSPAN1 association with EMT. Overall, TSPAN1 emerges as a novel oncogenic protein and a promising target for HNSCC therapy., This work was supported by grants from the Instituto de Salud Carlos III (ISCIII): PI15/01262 (M.E.LL.) PI19/00560 (J.M.G.-P.) and CP03/00101 (M.E.L.), CIBERONC (CB16/12/00390 to J.P.R.), Ayudas a Grupos PCTI Principado de Asturias (IDI2018/155 to J.P.R.), co-financed by the European Regional Fund (ERDF) and AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR (M.E.L.). Y.G.-M. and C.M. were granted by the VHIR and iP-FIS (ISCIII) fellowships respectively.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

TSPAN1, a Novel Protein Involved in Head and Neck Squamous Cell Carcinoma Chemoresistance

  • Garcia Mayea, Yoelsis|||0000-0002-9395-7471
  • Mir Pérez, Cristina|||0000-0003-3137-6521
  • Carballo, Laia
  • Castellvi, Josep|||0000-0001-5745-9996
  • Temprana-Salvador, Jordi|||0000-0001-9516-1680
  • Lorente Guerrero, Juan|||0000-0002-3264-0251
  • Benavente, Sergi|||0000-0002-2700-3522
  • García-Pedrero, Juana María|||0000-0002-5891-9488
  • Allonca, Eva|||0000-0002-2532-5421
  • Rodrigo, Juan Pablo|||0000-0003-3063-0890
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
Sensitization of resistant cells and cancer stem cells (CSCs) represents a major challenge in cancer therapy. A proteomic study revealed tetraspanin-1 (TSPAN1) as a protein involved in acquisition of cisplatin (CDDP) resistance (Data are available via ProteomeXchange with identifier PXD020159). TSPAN1 was found to increase in CDDP-resistant cells, CSCs and biopsies from head and neck squamous cell carcinoma (HNSCC) patients. TSPAN1 depletion in parental and CDDP-resistant HNSCC cells reduced cell proliferation, induced apoptosis, decreased autophagy, sensitized to chemotherapeutic agents and inhibited several signaling cascades, with phospho-SRC inhibition being a major common target. Moreover, TSPAN1 depletion in vivo decreased the size and proliferation of parental and CDDP-resistant tumors and reduced metastatic spreading. Notably, CDDP-resistant tumors showed epithelial-mesenchymal transition (EMT) features that disappeared upon TSPAN1 inhibition, suggesting a link of TSPAN1 with EMT and metastasis. Immunohistochemical analysis of HNSCC specimens further revealed that TSPAN1 expression was correlated with phospho-SRC (pSRC), and inversely with E-cadherin, thus reinforcing TSPAN1 association with EMT. Overall, TSPAN1 emerges as a novel oncogenic protein and a promising target for HNSCC therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neutrophil to Lymphocyte Ratio in Oropharyngeal Squamous Cell Carcinoma, A Systematic Review and Meta-Analysis

  • Rodrigo, Juan Pablo|||0000-0003-3063-0890
  • Sánchez-Canteli, Mario|||0000-0003-0343-0041
  • Triantafyllou, Asterios
  • de Bree, Remco|||0000-0001-7128-5814
  • Mäkitie, Antti A.|||0000-0002-0451-2404
  • Franchi, Alessandro|||0000-0002-1332-5838
  • Hellquist, Henrik
  • Saba, Nabil F.|||0000-0003-4972-1477
  • Stenman, Göran|||0000-0003-1017-7363
  • Takes, Robert P.
  • Valero Mayor, Cristina|||0000-0003-3397-2888
  • Zidar, Nina|||0000-0001-6866-3220
  • Ferlito, Alfio|||0000-0002-8247-8002
Neutrophil-to-lymphocyte ratio (NLR) in peripheral blood samples has been associated with prognosis in several cancers, including head and neck cancer, but in oropharyngeal carcinomas its prognostic value, especially in relation to human papillomavirus (HPV) infection, has been little studied. This meta-analysis, including studies on the prognostic value of NLR in oropharyngeal carcinoma, shows that an elevated pretreatment NLR is associated with a worse prognosis in oropharyngeal cancer, regardless of the type of treatment performed, but this prognostic value appears to be specific to HPV-positive oropharyngeal carcinomas. NLR could be used as an affordable prognostic marker in this type of cancer. Neutrophil-to-lymphocyte ratio (NLR) has been associated with survival in various cancers, including head and neck cancer. However, there is limited information on its role in oropharyngeal squamous cell carcinomas (OPSCC) according to HPV status. This prompted the present meta-analysis. Studies were selected when the prognostic value of NLR prior to treatment was evaluated in OPSCC patients, the cutoff value of NLR was available, and the prognostic value of NLR was evaluated by time-to-event survival analysis. A total of 14 out of 492 articles, including 7647 patients, were analyzed. The results showed a worse prognosis for the patients with a high NLR: The combined hazard ratios (HR) for overall survival (OS) in patients with an elevated NLR was 1.56 (95% confidence interval (CI) 1.21-2.02; p = 0.0006), for disease-free survival was 1.52 (95% CI 1.34-1.73; p < 0.00001), and for recurrence-free survival was 1.86 (95% CI 1.50-2.30; p < 0.00001). This worse prognosis of high NLR was exclusive of HPV-positive patients: HR for OS in the HPV-positive subgroup was 4.05 (95% CI 1.90-8.62 (p = 0.0003), and in the HPV-negative subgroup 0.92 (95% CI 0.47-1.80; p = 0.82). The prognosis of NLR was not influenced by treatment: The HR for OS for patients treated with radiotherapy/chemoradiotherapy (RT/CRT) was 1.48 (95% CI 1.09-2.01; p = 0.01), and for patients treated with surgery (±RT/CRT) was 1.72 (95% CI 1.08-2.72; p = 0.02). In conclusion, an elevated NLR relates to worse outcomes in patients with HPV-positive OPSCC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SDCBP modulates stemness and chemoresistance in head and neck squamous cell carcinoma through src activation

  • Mir Pérez, Cristina|||0000-0003-3137-6521
  • Garcia Mayea, Yoelsis|||0000-0002-9395-7471
  • García Fernández, Laia|||0009-0008-3105-493X
  • Herrero, Pol|||0000-0002-8746-7214
  • Canela, Núria|||0000-0003-0261-2396
  • Tabernero, Rocío|||0000-0002-5949-0898
  • Lorente Guerrero, Juan|||0000-0002-3264-0251
  • Castellvi, Josep|||0000-0001-5745-9996
  • Allonca, Eva|||0000-0002-2532-5421
  • García-Pedrero, Juana
  • Rodrigo, Juan Pablo|||0000-0003-3063-0890
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
To characterize the mechanisms that govern chemoresistance, we performed a comparative proteomic study analyzing head and neck squamous cell carcinoma (HNSCC) cells: CCL-138 (parental), CCL-138-R (cisplatin-resistant), and cancer stem cells (CSCs). Syntenin-1 (SDCBP) was upregulated in CCL-138-R cells and CSCs over parental cells. SDCBP depletion sensitized biopsy-derived and established HNSCC cell lines to cisplatin (CDDP) and reduced CSC markers, Src activation being the main SDCBP downstream target. In mice, SDCBP-depleted cells formed tumors with decreased mitosis, Ki-67 positivity, and metastasis over controls. Moreover, the fusocellular pattern of CCL-138-R cell-derived tumors reverted to a more epithelial morphology upon SDCBP silencing. Importantly, SDCBP expression was associated with Src activation, poor differentiated tumor grade, advanced tumor stage, and shorter survival rates in a series of 382 HNSCC patients. Our results reveal that SDCBP might be a promising therapeutic target for effectively eliminating CSCs and CDDP resistance.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

TSPAN1: A Novel Protein Involved in Head and Neck Squamous Cell Carcinoma Chemoresistance

  • Mir Perez, Cristina
  • Carballo Perich, Laia
  • Castellví Vives, Josep
  • Lorente Guerrero, Juan
  • Benavente Norza, Sergio
  • Lleonart Pajarin, Matilde
  • Temprana Salvador, Jordi
  • Garcia Mayea, Yoelsis
Apoptosi; Cèl·lules mare del càncer; Resistència, Apoptosis; Células madre cancerosas; Resistencia, Apoptosis; Cancer stem cells; Resistance, Sensitization of resistant cells and cancer stem cells (CSCs) represents a major challenge in cancer therapy. A proteomic study revealed tetraspanin-1 (TSPAN1) as a protein involved in acquisition of cisplatin (CDDP) resistance (Data are available via ProteomeXchange with identifier PXD020159). TSPAN1 was found to increase in CDDP-resistant cells, CSCs and biopsies from head and neck squamous cell carcinoma (HNSCC) patients. TSPAN1 depletion in parental and CDDP-resistant HNSCC cells reduced cell proliferation, induced apoptosis, decreased autophagy, sensitized to chemotherapeutic agents and inhibited several signaling cascades, with phospho-SRC inhibition being a major common target. Moreover, TSPAN1 depletion in vivo decreased the size and proliferation of parental and CDDP-resistant tumors and reduced metastatic spreading. Notably, CDDP-resistant tumors showed epithelial–mesenchymal transition (EMT) features that disappeared upon TSPAN1 inhibition, suggesting a link of TSPAN1 with EMT and metastasis. Immunohistochemical analysis of HNSCC specimens further revealed that TSPAN1 expression was correlated with phospho-SRC (pSRC), and inversely with E-cadherin, thus reinforcing TSPAN1 association with EMT. Overall, TSPAN1 emerges as a novel oncogenic protein and a promising target for HNSCC therapy., This work was supported by grants from the Instituto de Salud Carlos III (ISCIII): PI15/01262 (M.E.LL.) PI19/00560 (J.M.G.-P.) and CP03/00101 (M.E.L.), CIBERONC (CB16/12/00390 to J.P.R.), Ayudas a Grupos PCTI Principado de Asturias (IDI2018/155 to J.P.R.), co-financed by the European Regional Fund (ERDF) and AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR (M.E.L.). Y.G.-M. and C.M. were granted by the VHIR and iP-FIS (ISCIII) fellowships respectively.